MNG714
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.307
- MITOTIC_SPINDLE+0.267
- INTERFERON_ALPHA_RESPONSE+0.218
- NOTCH_SIGNALING+0.207
- E2F_TARGETS+0.205
- G2M_CHECKPOINT+0.199
- PROTEIN_SECRETION+0.187
- UNFOLDED_PROTEIN_RESPONSE+0.186
- PI3K_AKT_MTOR_SIGNALING+0.184
- UV_RESPONSE_DN+0.151
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.413
- HYPOXIA-0.370
- ANGIOGENESIS-0.285
- ESTROGEN_RESPONSE_LATE-0.224
- COAGULATION-0.222
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.211
- GLYCOLYSIS-0.209
- APOPTOSIS-0.178
- IL6_JAK_STAT3_SIGNALING-0.174
- ESTROGEN_RESPONSE_EARLY-0.153
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG361 | — | — | 0.812 |
| 2 | MNG573 | — | — | 0.787 |
| 3 | 20d40b1a-fbe0-4710-b0db-5c190e00addd | — | — | 0.768 |
| 4 | SJEPD031236_D1.RNA-Seq | EPN | Supratentorial EPN | 0.756 |
| 5 | MNG196 | — | — | 0.746 |
| 6 | MNG909 | — | — | 0.742 |
| 7 | 961CEC20-67F2-4615-8725-F35C12F0BC9B | — | — | 0.739 |
| 8 | d708a0d7-edda-46a8-b717-1b48c073c828 | — | — | 0.734 |
| 9 | MNG1220 | — | — | 0.725 |
| 10 | MNG1027 | — | — | 0.721 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.307 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.267 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.218 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.207 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.205 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.199 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.187 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.186 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.184 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.151 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.118 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.116 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.095 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.079 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.071 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.068 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.047 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.038 | Inavolisib | — uncovered |